Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human interleukin-2 (Ser125)
- Development stage
- Unknown
- Lead developer
- Beijing Pharmaceutical
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Recombinant human interleukin-2 (Ser125) is a biologic therapy being investigated for the treatment of autoimmune diseases, specifically rheumatoid arthritis. Developed by Beijing SL PHARM and evaluated in clinical trials by Peking University People's Hospital, this drug is a modified form of the cytokine interleukin-2 where the cysteine at position 125 is replaced by serine to improve stability. When administered at low doses, it selectively binds to the high-affinity IL-2 receptor on regulatory T cells (Tregs), promoting their expansion and function to restore immune tolerance without activating pro-inflammatory effector T cells. In clinical studies for rheumatoid arthritis, it has been evaluated as an add-on therapy to methotrexate and loxoprofen to address the dysfunction of Treg cells characteristic of the disease.
- Brand names
- Yuance
- Other names
- low-dose hrIL-2recombinant human interleukin-2IL-2 (Ser125)
02
Targets
HS (Heparan sulfate)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on recombinant human interleukin-2 (Ser125).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human interleukin-2 (Ser125).